<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Precis Oncol</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Precis Oncol</journal-id><journal-title-group><journal-title>NPJ Precision Oncology</journal-title></journal-title-group><issn pub-type="epub">2397-768X</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40000871</article-id><article-id pub-id-type="pmc">PMC11861308</article-id>
<article-id pub-id-type="publisher-id">816</article-id><article-id pub-id-type="doi">10.1038/s41698-025-00816-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A spatial transcriptomic signature of 26 genes resolved at single-cell resolution characterizes high-risk gastric cancer precursors</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Huang</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1115-2937</contrib-id><name><surname>Wichmann</surname><given-names>Ignacio A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sathe</surname><given-names>Anuja</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shum</surname><given-names>Miranda V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Grimes</surname><given-names>Susan M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Meka</surname><given-names>Rithika</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Almeda</surname><given-names>Alison</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Xiangqi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Jeanne</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7870-5703</contrib-id><name><surname>Nguyen</surname><given-names>Quan</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Summer S.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Amieva</surname><given-names>Manuel R.</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hwang</surname><given-names>Joo Ha</given-names></name><address><email>jooha@stanford.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ji</surname><given-names>Hanlee P.</given-names></name><address><email>genomics_ji@stanford.edu</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Division of Gastroenterology, Department of Medicine, </institution><institution>Stanford School of Medicine, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Division of Oncology, Department of Medicine, </institution><institution>Stanford School of Medicine, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04teye511</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution>Division of Obstetrics and Gynecology, Department of Obstetrics, Escuela de Medicina, </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>Santiago, 8331150 Chile </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04teye511</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution>Advanced Center for Chronic Diseases (ACCDiS), </institution><institution>Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>Santiago, 8331150 Chile </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00rqy9422</institution-id><institution-id institution-id-type="GRID">grid.1003.2</institution-id><institution-id institution-id-type="ISNI">0000 0000 9320 7537</institution-id><institution>Institute for Molecular Bioscience, </institution><institution>The University of Queensland, </institution></institution-wrap>Brisbane, QLD 4072 Australia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Pathology, </institution><institution>Stanford School of Medicine, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Quantitative Sciences Unit, Department of Medicine, </institution><institution>Stanford School of Medicine, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Neurosurgery, </institution><institution>Stanford School of Medicine, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/014qe3j22</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 8186</institution-id><institution>Stanford Cancer Institute, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Microbiology and Immunology, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA 94305 USA </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f54p054</institution-id><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8956</institution-id><institution>Department of Pediatrics, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA 94305 USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>9</volume><elocation-id>52</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Gastric cancer precursors demonstrate highly-variable rates of progression toward neoplasia. Certain high-risk precursors, such as gastric intestinal metaplasia with advanced histologic features, may be at up to 30-fold increased risk for progression compared to lower-risk intestinal metaplasia. The biological differences between high- and low-risk lesions have been incompletely explored. In this study, we use several clinical cohorts to characterize the microenvironment of advanced gastric cancer precursors relative to low-risk lesions using bulk, spatial, and single-cell gene expression assays. We identified a 26-gene panel which is associated with advanced lesions, localizes to metaplastic glands on histopathology, and is expressed in aberrant mature and immature intestinal cells not normally present in the healthy stomach. This gene expression signature suggests an important role of the immature intestinal lineages in promoting carcinogenesis in the metaplastic microenvironment. These findings may help to inform future biomarker development and strategies of gastric cancer prevention.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Predictive markers</kwd><kwd>Gastric cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id><institution>U.S. Department of Health &#x00026; Human Services | NIH | National Cancer Institute (NCI)</institution></institution-wrap></funding-source><award-id>R01HG006137</award-id><award-id>P01CA26577</award-id><award-id>K08CA252635</award-id><award-id>P01CA26577</award-id><award-id>R01HG006137</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><award-id>P01CA26577</award-id><principal-award-recipient><name><surname>Huang</surname><given-names>Robert J.</given-names></name><name><surname>Wichmann</surname><given-names>Ignacio A.</given-names></name><name><surname>Su</surname><given-names>Andrew</given-names></name><name><surname>Sathe</surname><given-names>Anuja</given-names></name><name><surname>Shum</surname><given-names>Miranda V.</given-names></name><name><surname>Grimes</surname><given-names>Susan M.</given-names></name><name><surname>Meka</surname><given-names>Rithika</given-names></name><name><surname>Shen</surname><given-names>Jeanne</given-names></name><name><surname>Han</surname><given-names>Summer S.</given-names></name><name><surname>Amieva</surname><given-names>Manuel R.</given-names></name><name><surname>Hwang</surname><given-names>Joo Ha</given-names></name><name><surname>Ji</surname><given-names>Hanlee P.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Gastric cancer (GC) is a leading source of global cancer morbidity and mortality<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Survival from GC both worldwide and in Western nations remains poor (under 35%)<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, due to advanced stages at time of diagnosis. The intestinal subtype makes up a substantial majority of GCs and follows a carcinogenic pathway termed Correa&#x02019;s cascade<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. This premalignant evolution involves the gastric mucosa progressing through a series of histopathologic changes: non-atrophic gastritis (NAG), chronic atrophic gastritis (CAG), gastric intestinal metaplasia (GIM), dysplasia and ultimately GC.</p><p id="Par3">GIM provides an opportunity for cancer interception, as it often persists as a distinct lesion with unique characteristics and poses a continued risk for GC. As a result, GIM lesions are easily recognizable on upper endoscopy. The prevalence of GIM is estimated to be 5&#x02013;10% of the general population in Western nations<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. However, only a very small subset of patients with GIM will progress to GC over long-term follow-up<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. Identifying this subset of &#x0201c;high-risk&#x0201d; GIM has become a high clinical priority and may lead to strategies of early detection and mortality reduction. One promising risk stratification tool is the Operative Link on Gastric Intestinal Metaplasia (OLGIM) staging framework<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. OLGIM scoring represents a composite endpoint which incorporates two features: metaplastic cellularity at the microscopic level and topographic extent at the anatomical level. The cellularity of metaplasia may be assessed using a visual-analog scale<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, or by manual annotation of the percentages of glands involved<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The cellularity within each of the two major regions of the stomach, the antrum and body, are calculated. The antral and body scores are then used to calculate the overall summary score, which ranges from zero (no GIM) to four (highest risk). Recent studies have demonstrated that advanced OLGIM lesions (Stages III or IV) are 25&#x02013;34 times more likely to progress to high-grade dysplasia or GC compared to early OLGIM lesions (Stage I)<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. As such, while both high- and low-OLGIM lesions are both precursors to GC, their natural history and clinical management are radically different.</p><p id="Par4">Most prior translational studies of GIM have not differentiated between high- and low-risk status. This is in part because scoring systems such as OLGIM have only recently been developed<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Another reason may be the manually-intensive nature required to clinically stage specimens using OLGIM, which requires both a dedicated biopsy protocol and pathologists with skill and experience in interpreting histologic severity<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The OLGIM staging system has recently been endorsed by a number of international guidelines<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>; as such, their use will increase worldwide in the coming years. There exists a critical need to better understand molecular and cellular differences between lesions on either end of this spectrum.</p><p id="Par5">Using an OLGIM-staged cohort, we identified a gene expression signature which characterizes advanced, high-risk GIM lesions (defined as OLGIM III or IV). This analysis used an integrated multi-omics approach that included conventional RNA sequencing (RNA-seq), spatial transcriptomics analysis, single-cell RNA sequencing (scRNA-seq), and single-molecule fluorescent in situ hybridization (smFISH). In summary, we discovered a spatially-mapped high-risk gene expression signature which characterizes advanced GIM lesions, is shared by intestinal-type GCs, and localizes to aberrant mature and immature intestinal cells within the metaplastic microenvironment.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>Cohorts</title><p id="Par6">We provide an overview of the specimen sourcing in Supplementary Data <xref rid="MOESM2" ref-type="media">1</xref>. The Gastric Precancerous Conditions Study (<bold>GAPS</bold>) is a prospective cohort of individuals undergoing endoscopy who are at increased risk for GC due to presence of symptoms (e.g., dyspepsia, anemia), personal history (e.g., GIM), or family history of GC. Enrolled subjects undergo biopsies according to the updated Sydney System, with standardized histologic assessment allowing for calculation of OLGIM stage and determination of <italic>Helicobacter pyori</italic> (<bold>Hp</bold>) colonization. Sample-level phenotypic data and RNA sequencing metrics can be found in Supplementary Data <xref rid="MOESM2" ref-type="media">2</xref>. Notably, while GAPS recruits patients with active and eradicated Hp infection, we chose to develop the bulk expression signature only in patients who were negative for Hp at time of tissue collection in order to remove active Hp gastritis as a confounding variable in the analysis.</p><p id="Par7">The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) genomic dataset is comprised of GC samples which had not been previously treated by chemotherapy or radiation prior to genomic analysis<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. From these samples, we analyzed gene expression data from 180 intestinal-type GC primary tumors and 18 patient-matched tumor-adjacent controls. We obtained the de-identified patient clinical phenotype and RNA-seq results from Genomic Data Commons through TCGABiolinks<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> R package. Tumor-level phenotypic data (e.g., tumor location) is available in Supplementary Data <xref rid="MOESM2" ref-type="media">3</xref>.</p><p id="Par8">We analyzed a scRNA-seq dataset for gastric pathology across Correa&#x02019;s cascade (normal, NAG, CAG, GIM, and GC). This sample set constituted both de novo scRNA-seq data from prospectively collected samples along with public data sets. In total, the integrated scRNA-seq dataset comprised 40 biopsy samples from 26 patients: two normal controls, three NAG, three CAG, thirteen GIM, nine tumor-adjacent controls, and ten primary gastric tumors. Clinical phenotypic information (specimen location and histology), cell counts, and sequencing metrics are available in Supplementary Data <xref rid="MOESM2" ref-type="media">4</xref>.</p><p id="Par9">For the spatial mapping and localization, we used formalin-fixed paraffin-embedded (FFPE) tissues from five patients (four GIM, one GC). The hematoxylin and eosin (H&#x00026;E)-stained sections were manually annotated by an expert pathologist at the glandular level for regions of normal base, normal pit, metaplasia, dysplasia, and carcinoma. For spatial transcriptomics, unstained sections were placed on the Visium assay slide (10X Genomics) and stained with H&#x00026;E followed by probe-based sequencing. For the single-molecule multiplex fluorescence in situ hybridization (smFISH) assays, we used unstained sections immediately adjacent (within 10 <italic>&#x003bc;</italic>m) to the Visium sections. Description of the specimens used for spatial validation are available in Supplementary Data <xref rid="MOESM2" ref-type="media">5</xref>.</p></sec><sec id="Sec4"><title>Overview of the multi-omics approach</title><p id="Par10">An overview of the multi-omics pipeline is provided in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. In brief, this analysis included the following: (i) discovery of a high-risk gene expression signature using RNA-seq data (<italic>N</italic>&#x02009;=&#x02009;88 samples; GAPS); (ii) validation of the high-risk genes in a held-out cohort using RNA-seq data (<italic>N</italic>&#x02009;=&#x02009;215 samples; GAPS); (iii) mapping of the high-risk genes to metaplastic foci using a spatial transcriptomics assay (<italic>N</italic>&#x02009;=&#x02009;5 samples; spatial cohort); (iv) determining of the overlap of the high-risk GIM spatial signature with differentially expressed genes in intestinal-type GC samples with RNA-seq data (<italic>N</italic>&#x02009;=&#x02009;198 samples; TCGA); (v) assigning the high-risk, spatially mapped genes to specific cell subpopulations using single cell RNA-seq (scRNA-seq) (<italic>N</italic>&#x02009;=&#x02009;40 samples; scRNA-seq cohort); and (vi) validation of a subset of these genes at single cell resolution using smFISH (<italic>N</italic>&#x02009;=&#x02009;5 samples; spatial cohort). Genes selected at each step are outlined in Supplementary Data <xref rid="MOESM2" ref-type="media">6</xref>&#x02013;<xref rid="MOESM2" ref-type="media">9</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><title>Overview of study design.</title><p>Multi-omics flow diagram demonstrating process of discovering and orthogonally validating gene marker panel. At each step, the number of marker genes is shown. This figure was created with BioRender.com.</p></caption><graphic xlink:href="41698_2025_816_Fig1_HTML" id="d33e561"/></fig></p></sec><sec id="Sec5"><title>Gene expression analysis of high- versus low-risk GIM</title><p id="Par11">For the GAPS-based marker discovery phase, a detailed summary of the cohort&#x02019;s demographic, clinical and histologic characteristics are provided in Table <xref rid="Tab1" ref-type="table">1</xref>. The cohort was enriched for Asians (43%) and Hispanics (24%). When assessing OLGIM stages, 56.4% were OLGIM stage 0 (no GIM), 16.6% OLGIM I, 13.5% OLGIM II, 9.2% OLGIM III, and 4.2% OLGIM IV.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical and histopathologic attributes of GAPS cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Enrolled subjects (<italic>N</italic>&#x02009;=&#x02009;163)</th><th colspan="2">Unique gastric biopsies (<italic>N</italic>&#x02009;=&#x02009;303)</th></tr><tr><th>Characteristic</th><th>Frequency (%)</th><th>Finding</th><th>Frequency (%)</th></tr></thead><tbody><tr><td>Age</td><td/><td>All biopsies</td><td/></tr><tr><td>&#x02003;&#x0003c;50</td><td>40 (24.5)</td><td>&#x02003;Normal/NAG</td><td>204 (67.3)</td></tr><tr><td>&#x02003;50&#x02013;69</td><td>90 (55.2)</td><td>&#x02003;CAG</td><td>99 (32.7)</td></tr><tr><td>&#x02003;&#x0003e;70</td><td>33 (20.2)</td><td>&#x02003;GIM severity</td><td>96 (31.7)</td></tr><tr><td>Female</td><td>105 (63.1)</td><td>&#x02003;&#x02003;Mild</td><td>42 (13.9)</td></tr><tr><td>Race/Ethnicity</td><td/><td>&#x02003;&#x02003;Moderate</td><td>31 (10.2)</td></tr><tr><td>&#x02003;Non-Hispanic White</td><td>37 (22.7)</td><td>&#x02003;&#x02003;Severe</td><td>23 (7.6)</td></tr><tr><td>&#x02003;Black</td><td>1 (0.6)</td><td>Antrum</td><td>(<italic>N</italic>&#x02009;=&#x02009;153)</td></tr><tr><td>&#x02003;Hispanic</td><td>39 (23.9)</td><td>&#x02003;Normal/NAG</td><td>92 (60.7)</td></tr><tr><td>&#x02003;East Asian</td><td>70 (42.9)</td><td>&#x02003;CAG</td><td>61 (39.9)</td></tr><tr><td>&#x02003;Other</td><td>16 (9.8)</td><td>&#x02003;GIM severity</td><td>60 (39.2)</td></tr><tr><td>Foreign born</td><td>102 (62.6)</td><td>&#x02003;&#x02003;Mild</td><td>26 (17.0)</td></tr><tr><td>Family history*</td><td>16 (9.8)</td><td>&#x02003;&#x02003;Moderate</td><td>20 (13.1)</td></tr><tr><td>Proton pump inhibitor use</td><td>53 (20.4)</td><td>&#x02003;Severe</td><td>14 (9.2)</td></tr><tr><td>OLGIM stage**</td><td/><td>Body</td><td>(<italic>N</italic>&#x02009;=&#x02009;150)</td></tr><tr><td>&#x02003;0 (no GIM)</td><td>92 (56.4)</td><td>&#x02003;Normal/NAG</td><td>112 (74.7)</td></tr><tr><td>&#x02003;I (lowest)</td><td>27 (16.6)</td><td>&#x02003;CAG</td><td>38 (25.3)</td></tr><tr><td>&#x02003;II</td><td>22 (13.5)</td><td>&#x02003;GIM severity</td><td>36 (24.0)</td></tr><tr><td>&#x02003;III</td><td>15 (9.2)</td><td>&#x02003;&#x02003;Mild</td><td>16 (10.7)</td></tr><tr><td>&#x02003;IV (highest)</td><td>7 (4.2)</td><td>&#x02003;&#x02003;Moderate</td><td>11 (7.3)</td></tr><tr><td/><td/><td>&#x02003;&#x02003;Severe</td><td>9 (6.0)</td></tr></tbody></table><table-wrap-foot><p>Table 1 represents prospectively-recruited patients through GAPS (GAstric Precancerous conditions Study); clinical information on samples drawn from publicly-available data sources (e.g., TCGA cohort), as well as cancer resection specimens are not included in Table. *Family history defined as a first-degree relative diagnosed with gastric adenocarcinoma. **Gastric intestinal metaplasia (GIM) severity scores used to calculate operative link (OLGIM) stage. NAG, non-atrophic gastritis; CAG, chronic atrophic gastritis.</p></table-wrap-foot></table-wrap></p><p id="Par12">We used conventional RNA-seq to analyze 303 gastric specimens (153 antrum, 150 body) originating from 163 unique individuals from GAPS (specimen-level data on histopathology and sequencing metrics are provided in Supplementary Data <xref rid="MOESM2" ref-type="media">2</xref>). These samples were obtained at the same time point. Samples were stratified as high-risk if OLGIM stage was III or IV or operationally defined as low-risk if OLGIM&#x02009;&#x0003c;&#x02009;III. The cohort was separated into a discovery set of 88 samples (22 high-risk, 66 low-risk) from 46 patients and a held-out validation set of 215 samples (22 high-risk, 193 low-risk) from 115 patients. The discovery and validation sets were balanced with regards to the number of high-risk specimens; moreover, both sets had equal distribution of antral and body samples. Prior to differential expression analysis, we performed unsupervised clustering through (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>) to confirm preferential grouping of high-risk and low-risk samples. Subsequently, we conducted differential expression analysis with limma-voom<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, utilizing a factorial design strategy (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>).</p></sec><sec id="Sec6"><title>Discovery of genes associated with high-risk GIM</title><p id="Par13">From the discovery set, we identified a preliminary list of 399 genes that were differentially expressed in the high-risk samples (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3A&#x02013;C</xref><bold>;</bold> Supplementary Data <xref rid="MOESM2" ref-type="media">6</xref>). Likewise, we excluded any genes which differential expression profile differed significantly between antrum and body (Supplementary Fig. <xref rid="MOESM1" ref-type="media">3D</xref>). Next, we conducted weighted gene co-expression network analysis (WGCNA)<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> to determine groups of co-expressed genes, otherwise referred to as gene modules. Using hierarchical clustering with Pearson correlation distance, we demonstrated that genes from two modules were informative of high-risk gastric cancer precursors, whereas five other modules were not informative (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>).</p><p id="Par14">We intersected genes from the two informative WGCNA modules and the differential expression analysis, resulting in a refined set of 314 genes that were: (i) differentially expressed in high-risk samples from both anatomic regions, and (ii) co-expressed in gene modules associated with high-risk stages (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Supplementary Data <xref rid="MOESM2" ref-type="media">6</xref>). From this subset of 314 genes, we identified five discrete expression clusters that were labeled C-1 through C-5 (<italic>side dendrogram</italic>). Cluster C-5 represented a subset of 105 genes which were overexpressed in high- compared to low-risk samples, with the highest Z-scores. This gene set included established GIM markers such as <italic>CDX1</italic>, <italic>FABP1</italic> and <italic>ACE2</italic>. In addition to markers of mature enterocytes (<italic>ANPEP</italic>, <italic>CDH17</italic>)<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>, we also found markers of intestinal stem cells (such as <italic>OLFM4</italic>)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, and other immature intestinal lineages such as transit-amplifying cells (<italic>DMBT1</italic>)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. We termed the population of immature cells found in the gastric epithelium expressing intestinal stem cell markers as &#x0201c;intestinal-like stem cells&#x0201d;.<fig id="Fig2"><label>Fig. 2</label><caption><title>Discovery and validation of the high-risk expression signature.</title><p><bold>a</bold> Heatmap and hierarchical clustering of differentially expressed and co-expressed genes from the discovery cohort of 88 samples, 22 high-risk (defined as operative link stages III-IV) and 66 low-risk (defined as operative link stages 0-II). Most of the high-risk samples clustered distinctly and separately from the low-risk group, regardless of the anatomic site of the biopsy (top dendrogram). A set of genes were found to be both differentially expressed between high- and low-risk samples. Cluster-5 (C-5) represents 105 genes which were selectively upregulated in their expression only in high-risk samples, regardless of anatomic location. <bold>b</bold> We found 100 genes from C-5 to be differentially upregulated in the validation cohort (22 high-risk and 193 low-risk samples), confirming a robust signature for high-risk GIM which is agnostic of location. Dot plot depicting over-representation analysis results of these 100 genes: (<bold>c</bold>) gene ontology terms are enriched with intestinal processes (e.g., brush border, intestinal absorption); (<bold>d</bold>) cell type signature gene sets are enriched for mature and immature/fetal intestinal cell types.</p></caption><graphic xlink:href="41698_2025_816_Fig2_HTML" id="d33e902"/></fig></p></sec><sec id="Sec7"><title>Validating the genes associated with high-risk GIM</title><p id="Par15">Next, we validated these results in the independent validation set of 215 samples. For the 105 genes identified from the C-5 cluster in the discovery set, we found a striking 100 out of 105 genes (95.2%) consistently overexpressed among the validation set&#x02019;s high-risk samples (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The full gene list is provided in Supplementary Data <xref rid="MOESM2" ref-type="media">7</xref>. To characterize the functional pathways and cellular associations of these 100 genes, we conducted over-representation analyses with clusterProfiler<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. We selected gene sets relative to gene ontology and cell types from the MSigDB database<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>. Enriched gene ontology terms (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>) included intestinal absorption (<italic>SLC2A5</italic>, <italic>ABCG8</italic>, <italic>ABCG5</italic>, <italic>MOGAT2</italic>, <italic>PRAP1</italic>, <italic>FABP1</italic>) and presence of a brush border (<italic>ACE2</italic>, <italic>SLC28A1</italic>, <italic>SLC2A2</italic>, <italic>MME</italic>, <italic>SLC6A19</italic>, <italic>SLC7A9</italic>, <italic>MTTP</italic>, <italic>MYO7B</italic>) among other intestinal-related processes. Consistent with these findings, we found enrichment of certain cell lineage gene sets (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>) including mature (<italic>SLC2A5</italic>, <italic>APOC3</italic>, <italic>ACE2</italic>) and fetal enterocytes (<italic>LRRC19</italic>, <italic>CELP</italic>, <italic>RBP2</italic>), as well as immature enterocytes (<italic>DMBT1</italic>, <italic>CPS1</italic>). A comprehensive listing of enriched gene ontology terms and cell lineage gene sets are available in Supplementary Data <xref rid="MOESM2" ref-type="media">10</xref>, <xref rid="MOESM2" ref-type="media">11</xref>.</p></sec><sec id="Sec8"><title>Spatial transcriptomics maps the high-risk expression signature to metaplastic foci</title><p id="Par16">Next, we used a spatial expression assay (Visium, 10X Genomics) to map the genes of the high-risk expression signature to GIM regions. We generated extensive histopathology annotation for these samples, all which included regions of (i) normal base, (ii) normal pit or (iii) metaplastic foci. An example of one GIM sample (<bold>P09788</bold>) is shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The aggregated spots per region for each sample were used to conduct a differential expression analysis comparing regions of metaplasia vs normal pit or base, using a &#x02018;pseudo-bulk&#x02019; analysis. Significantly upregulated genes were defined as those with a positive fold-change and an FDR-adjusted <italic>P</italic> value&#x02009;&#x02264;&#x02009;0.05. Among all samples, we determined that 458 genes were significantly upregulated in regions of metaplastic foci compared to both normal gland base and pit (Supplementary Data <xref rid="MOESM2" ref-type="media">8</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Spatial resolution of the high-risk signature.</title><p><bold>a</bold> An example of the expression profile of <italic>DMBT1</italic> upon a Visium slide annotated by a pathologist for areas of normal glandular architecture (base and pit) and metaplasia. <italic>DMBT1</italic> is shown as an example of a spatially resolved gene mapping to pathologist-annotated metaplasia, whereas <italic>SLC30A10</italic> is shown as an example of a gene not mapping to metaplasia and, thus, discarded form the spatially-resolved signature. <bold>b</bold> Heatmap depicting 36 differentially expressed genes from spatial pseudobulk analysis that overlapped with bulk RNA-seq signature from GAPS (FDR-adjusted <italic>P</italic> value&#x02009;&#x02264;&#x02009;0.05; analysis performed using limma-voom). <bold>c</bold> Scatter plot showing log2 fold-change of 36 upregulated genes from the spatial cohort (X-axis) and log2 fold-change from TCGA. Twenty-six genes overexpressed in both analyses are shown in red. <bold>d</bold> Spatial mapping of the refined 26-gene signature onto Visium spots. <bold>e</bold> Comparison of 26-gene signature between metaplastic foci vs normal stomach base or pit (Kruskal-Wallis and Dunn test FDR-adjusted <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). Note: each Visium spot is 55&#x02009;&#x000b5;m in diameter, with 100&#x02009;&#x000b5;m distance between the center of adjacent spots.</p></caption><graphic xlink:href="41698_2025_816_Fig3_HTML" id="d33e1064"/></fig></p><p id="Par17">Next, we intersected the 100 genes from the validated expression signature as previously described with the 458 genes that were mapped using the spatial transcriptomic assay. Notably, from the validated expression signature, 36 out of 100 (36%) genes were expressed specifically in regions of the metaplastic glands (e.g., <italic>DMBT1</italic>, Fig. <xref rid="Fig3" ref-type="fig">3a</xref>; other spatially resolved genes in Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Overall, this result identified a subset of 36 high-risk differentially expressed genes that mapped to pathologist-annotated regions of metaplasia.</p></sec><sec id="Sec9"><title>The high-risk expression, spatially mapped signature&#x02019;s association with gastric cancer</title><p id="Par18">We determined how many of the 36 spatially mapped high-risk genes were also differentially expressed in the intestinal subtype of GC. This step of the analysis used RNA-seq data from the TCGA-STAD cohort. We conducted differential gene expression analysis between 180 gastric cancers, all being of the intestinal subtype, and 18 matched tumor-adjacent gastric tissues. We compared the fold-change from the TCGA analysis vs the fold-change from the spatial gene expression analysis for the 36 genes (Supplementary Data <xref rid="MOESM2" ref-type="media">9</xref>). Twenty-six genes overlapped between those which were significantly overexpressed in high-risk GIM (relative to low-risk GIM), localized to metaplastic foci, and were consistently upregulated in GC (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>).</p><p id="Par19">We quantified the expression of these 26 genes in gastric metaplastic foci using a composite signature score<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. The 26-gene score was significantly higher among the Visium spots mapping to metaplastic foci for each of the five spatial samples compared to areas with normal stomach base or pit (Kruskal-Wallis and Dunn test FDR-adjusted <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) (Fig. <xref rid="Fig3" ref-type="fig">3d</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">5</xref>). Overall, this set was highly specific for metaplasia and did not map to any other normal gastric regions. The gene signature included established markers for immature intestinal lineages (<italic>OLFM4</italic>, <italic>DMBT1</italic>)<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> and markers for mature enterocytes (<italic>ANPEP</italic>, <italic>CDH17</italic>)<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>.</p></sec><sec id="Sec10"><title>The high-risk spatial signature is expressed in both enterocytes and intestinal-like stem cells</title><p id="Par20">We used scRNA-seq to determine the 26 gene signature across all cells in the 40 specimens of GC, precancerous lesions, and normal samples. The joint data set contained a total of 116,643 single cells. From this data set we identified nine major cell lineages: epithelial, T cells and NK cells, B cells, stromal cells (fibroblasts), plasma cells, endothelial, myeloid (macrophages and dendritic cells), mast cells, and smooth muscle cells. This signature was highly specific to the subset of epithelial cells (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6</xref> and Supplementary Data <xref rid="MOESM2" ref-type="media">12</xref>).</p><p id="Par21">We next analyzed the epithelial cell subset at the single-cell level. We annotated 18 cell clusters based on expression of specific markers (Fig. <xref rid="Fig4" ref-type="fig">4A</xref> and Supplementary Fig. <xref rid="MOESM1" ref-type="media">7</xref>). We first identified broadly gastric (<italic>TFF2</italic>, <italic>MUC5AC</italic>) and broadly intestinal (<italic>REG4</italic>) cells. The gastric cell clusters included chief cells (<italic>LIPF</italic>, <italic>PGA3</italic>, <italic>PGA4</italic>, <italic>PGA5</italic>), parietal cells (<italic>ATP4A</italic>, <italic>ATP4B</italic>, <italic>GIF</italic>, <italic>CKB</italic>), isthmus cells (<italic>STMN1</italic>, <italic>MKI67</italic>, <italic>HMGB2</italic>), pit cells (<italic>CAPN8</italic>, <italic>TFF1</italic>, <italic>GKN1</italic>, <italic>GKN2</italic>, <italic>SULT1C2</italic>), endocrine G cells (<italic>NKX6-3</italic>, <italic>GAST</italic>, <italic>CHGB</italic>), LYZ-positive/neck cells (<italic>AQP5</italic>, <italic>MUC6</italic>, <italic>PRR4</italic>, <italic>LYZ</italic>), and metallothionein-expressing cells (<italic>MT1X</italic>, <italic>MT2A</italic>, <italic>MT1G</italic>, <italic>MT1H</italic>, <italic>MT1E</italic>).<fig id="Fig4"><label>Fig. 4</label><caption><title>Single-cell identification of cell types expressing the high-risk signature.</title><p><bold>A</bold> Uniform Manifold Approximation and Projection (UMAP) plot showing reference-mapped epithelial cells. <bold>B</bold> UMAP plot showing module score by epithelial cell type. <bold>C</bold> Comparison of the module score between cell types using all 40 samples from the scRNA-seq cohort. TA, transit amplifying cells. <bold>D</bold> Heatmap showing the scaled expression of the 26 genes by cell type. <bold>E</bold> Stacked bar plots depicting the proportion of cell types per sample, ordered by stage of Correa&#x02019;s cascade. Gastric lineages are aggregated into a single class. EGC Early gastric cancer. <bold>F</bold> Comparison of module score across Correa&#x02019;s cascade (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001 for all comparisons). <bold>G</bold> Comparison of the module score between GC and tumor-adjacent control tissues (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p></caption><graphic xlink:href="41698_2025_816_Fig4_HTML" id="d33e1282"/></fig></p><p id="Par22">Among REG4<sup>+</sup> intestinal lineages, we identified clusters of early and mature enterocytes (<italic>CDH17</italic>, <italic>FABP1</italic>, <italic>FABP2</italic>, <italic>KRT20</italic>, <italic>GPA33</italic>), goblet cells (<italic>SPINK4</italic>, <italic>MUC2</italic>, <italic>TFF3</italic>), transit-amplifying cells (<italic>DMBT1</italic>), and intestinal-like stem cells (<italic>OLFM4</italic>, <italic>LEFTY1</italic>). Intestinal-like stem cells shared some common transcriptional features with isthmus cells, including expression of <italic>MKI67</italic>, <italic>STMN1</italic> and <italic>HMGB2</italic>. Roughly 10% of intestinal-like stem cells expressed <italic>CDCA7</italic>, similar to what was observed in LYZ-positive/neck cells. Interestingly, a small fraction of these cells (~5%) also expressed <italic>LGR5</italic>, which was again found with a similar percentage among LYZ-positive/neck cells. We collectively termed immature cells with intestinal features (mixed gastric/intestinal precursors, early enterocytes, transit amplifying cells, and intestinal-like stem cells) as &#x0201c;immature intestinal cells&#x0201d; for the purposes of further analysis. We found distinct sets of genes from the 26-gene signature to be significantly enriched in mature enterocytes compared to immature intestinal cells (Fig. <xref rid="Fig4" ref-type="fig">4B, C</xref>, Supplementary Data <xref rid="MOESM2" ref-type="media">13</xref>). Notably, the 26-gene signature was nearly absent among all normal gastric lineages.</p><p id="Par23">Next, we examined the expression of each gene scaled across the epithelial cell types to highlight which cells displayed the highest levels of expression. As a specific marker for goblet cells was not part of the original signature, we also included the gene <italic>TFF3</italic><sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. The gene dendrogram revealed three distinct groups of genes; six genes expressed by all intestinal lineages (<italic>ADH6, SLC39A5, GUCY2C, CLDN3, ONECUT2</italic>, and <italic>CDX1</italic>), 16 genes expressed by only mature intestinal lineages (<italic>MYO7B, FLVCR2, RNF186, HKDC1, SLC7A9, SLC6A19, PRAP1, TM4SF20, MEP1A, VNN1, ANPEP, BTNL3, CDH17, EFNA2, ANXA13</italic>, and <italic>CHP2</italic>), and four genes expressed preferentially by immature intestinal cells (<italic>OLFM4</italic>, <italic>ADGRG7, CPS1</italic>, and <italic>DMBT1</italic>) (Fig. <xref rid="Fig4" ref-type="fig">4D</xref>). Some genes like <italic>CPS1</italic>, despite being expressed predominantly by intestinal-like stem cells, were also expressed (at lower levels) among differentiated enterocytes. Similarly, some genes (such as <italic>HKDC1</italic>) showed strongest expression levels in differentiated enterocytes but were also expressed to a lesser degree among intestinal-like stem cells.</p><p id="Par24">We analyzed the proportion of different cell lineages throughout Correa&#x02019;s cascade (Fig. <xref rid="Fig4" ref-type="fig">4E</xref>). Normal, NAG, and CAG gastric tissue samples were mostly devoid of intestinal cells. In contrast, GIM was characterized by strong presence of both mature and immature intestinal lineages. Interestingly, GC was characterized by a significant enrichment of intestinal-like stem cells and substantial relative loss of differentiated goblet cells and enterocytes. These results suggest that the continued expansion of immature intestinal populations in GIM may be an important indicator and contributor to progression of intestinal-type GC. Next, we observed that the 26-gene signature score increased with the progressive stages of Correa&#x02019;s cascade and in GC compared with tumor-adjacent controls (Supplementary Data <xref rid="MOESM2" ref-type="media">14</xref>, Supplementary Data <xref rid="MOESM2" ref-type="media">15</xref>, and Fig. <xref rid="Fig4" ref-type="fig">4F</xref>). Notably, there was a significant increase in the signature module score in tumor-adjacent GIMs compared to GIM from non-cancer patients. In a separate analysis, we analyzed the signature score between GCs and patient-matched tumor adjacent control tissues from a previous publication from our group<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> (Fig. <xref rid="Fig4" ref-type="fig">4G</xref>). As expected, we found the 26-gene signature to be significantly increased in tumor cells relative to tumor-adjacent gastric tissue (Welch&#x02019;s <italic>T</italic> test <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p></sec><sec id="Sec11"><title>Single-molecule fluorescent in situ hybridization reveals intestinal-like stem cells in the isthmic/crypt region of metaplastic glands</title><p id="Par25">The smFISH assay uses in situ RNA hybridization to visualize the spatial expression of up to twelve genes at single-molecule subcellular resolution and enables simultaneous incorporation of spatial and cellular-level gene expression data. Based on the scRNA-seq results that defined the aberrant intestinal-like stem cell populations, we selected eleven of the signature genes for smFISH. These genes included markers for immature intestinal cells (<italic>OLFM4, CPS1, DMBT1)</italic>, enterocytes (<italic>HKDC1, ANPEP, CDH17, CLDN3, ANXA13</italic>), or were expressed across all intestinal lineages (<italic>CDX1, SLC39A5, ONECUT2</italic>). We also included <italic>TFF3</italic> as a specific goblet cell marker. After imaging, the results were compared to the matching H&#x00026;E images with pathology interpretation.</p><p id="Par26">Notably, none of the selected genes were expressed in the normal gastric glands across any of the samples. We identified several distinct cellular compartments which occurred solely within metaplastic tissue (Fig. <xref rid="Fig5" ref-type="fig">5</xref>, Supplementary Figs. <xref rid="MOESM1" ref-type="media">8</xref>&#x02013;<xref rid="MOESM1" ref-type="media">10</xref>). The first compartment consisted of mature or differentiated intestinal cells and were characterized by strong expression of <italic>TFF3</italic> (goblet cells) and moderate <italic>ANPEP</italic> signal (enterocytes). A second compartment consisted of cells which strongly expressed stem markers (O<italic>LFM4, DMBT1</italic> and <italic>CPS1</italic>); these columnar cells were characterized by high nuclear-to-cytoplasm ratio, were located near crypt regions of metaplastic glands, and were mutually exclusive in space to the mature markers. These results provide additional evidence confirming the presence of intestinal-like stem cells as previously identified in the scRNA-seq results. There were some genes (<italic>ONECUT2</italic> and <italic>HDKC1</italic>) which were ubiquitously expressed in both mature and immature cells. However, their expression was notably higher among the O<italic>LFM4, DMBT1</italic> and <italic>CPS1</italic>-positive stem cells at the gland isthmic/crypt region. In one early GC sample, we observed that the expression levels of immature intestinal cell markers (<italic>OLFM4</italic>, <italic>DMBT1</italic>, and <italic>CPS1</italic>) along with <italic>CDX1</italic> and <italic>HKDC1</italic>, were significantly higher in a region containing poorly differentiated tumor glands compared to an area with well-differentiated tumor glands, which prominently expressed <italic>TFF3</italic> (Supplementary Fig. <xref rid="MOESM1" ref-type="media">11</xref>). These findings align with the cell phenotypes seen in H&#x00026;E staining and reflect the molecular characteristics of both intestinal-like stem cell regions and the differentiated goblet and enterocyte areas observed in GIM. The results from smFISH provided single-cell spatial resolution and confirmed the presence of distinct cellular compartments within metaplastic glands consisting of either mature intestinal lineages (enterocytes and goblet cells) or immature lineages.<fig id="Fig5"><label>Fig. 5</label><caption><title>Single-molecule fluorescence in situ hybridization (smFISH) of gastric intestinal metaplasia (GIM).</title><p><bold>A</bold>, <bold>B</bold> Representative region showing H&#x00026;E staining of GIM from sample P08563 (operative link III), and superimposed smFISH characterization for six genes: <italic>OLFM4, CPS1, HKDC1, DMBT1, ANPEP</italic>, and <italic>TFF3</italic>. <bold>C</bold>, <bold>D</bold> Inset magnification for highlighted area from (<bold>A</bold>) and (<bold>B</bold>), respectively (90-degree clockwise rotation). <bold>E</bold> Highlighted regions in (<bold>C</bold>) and (<bold>D</bold>), showing H&#x00026;E and individual channels from areas enriched for intestinal-like stem cells. These cells show elevated expression of <italic>OLFM4, DMBT1, CPS1</italic>, and <italic>HKDC1</italic>, together with moderate expression of <italic>ANPEP</italic>. <bold>F</bold> Highlighted regions in (<bold>C</bold>) and (<bold>D</bold>), showing H&#x00026;E and individual channels from areas enriched for well-differentiated (mature) cells. These cells show elevated expression of <italic>TFF3</italic> and moderate expression of <italic>ANPEP</italic>. The expression of these genes was mutually exclusive, in space, from the immature cell markers.</p></caption><graphic xlink:href="41698_2025_816_Fig5_HTML" id="d33e1556"/></fig></p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p id="Par27">In this study, we analyzed a cohort of individuals with pathology across the gastric precancerous spectrum. Using integrated bulk gene expression, spatial transcriptomics, scRNA-seq, and smFISH, we identified a highly refined signature of 26 genes which characterizes both the presence and cellularity of metaplasia within gastric glands. Notably, this set of genes is expressed by aberrant epithelial cells not typically found in healthy gastric tissue, reflects the presence of both mature intestinal lineages, such as goblet cells and enterocytes, and immature intestinal lineages, including intestinal-like stem cells within the metaplastic foci. Furthermore, this discrete gene set holds potential for distinguishing between these mature and immature aberrant lineages.</p><p id="Par28">While this high-risk gene expression signature is characterized by both markers of mature enterocytes and stem cells, we found that the more advanced lesions had greater expression of immature intestinal markers. This progression was characterized by increased expression of intestinal-like stem cell markers such as <italic>OLFM4</italic><sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, as well as markers of transit-amplifying cells such as <italic>DMBT1</italic><sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. These markers were absent from both normal differentiated gastric tissues, as well as gastric stem cells. Collectively, these results point to immature intestinal cells playing an important, constitutive role in the biology of advanced preneoplasia. A recent cohort study of a high-risk Chinese Singaporean population followed patients with GIM to neoplasia, and analyzed GIM tissue using a combination of single-cell and spatial analyses<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. This study similarly found GIM tissue to consist of enterocyte-dominant and stem-cell-dominant regions, with expansion of the stem-cell-dominant compartment linked to early malignancy. Our study importantly complements and validates the Singaporean study by offering a similar biological conclusion in a vastly different population; at the same time, our study offers further spatial refinement on the location and origin of these intestinal-like stem cell compartments through smFISH. In addition, another recent report demonstrated phenotypic mosaicism in GIM, by which individual GIM cells co-express both intestinal and gastric markers<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. This interesting finding strongly suggests that the intestinal cells identified by our studies also possess gastric transcriptional properties. Future efforts should be made to fully characterize these cell populations. Our data lend further credence to the hypothesis that terminally-differentiated epithelial cells (such as enterocytes and goblet cells) may simply be passive bystanders harboring genetic alterations already present in genetically unstable stem cells, the latter of which have the potential to become the true carcinogenic precursors<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p><p id="Par29">Among the genes from the high-risk signature, some correspond to known markers for immature intestinal cells, including <italic>OLFM4</italic> and <italic>DMBT1</italic>. Other genes in the signature are established markers for mature enterocytes. For example, <italic>ANPEP</italic> encodes aminopeptidase N, and an early report suggested that leucine aminopeptidase activity was highly specific to metaplastic zones within the human stomach examined microscopically<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. <italic>CDH17</italic> is a membrane-associated enterocyte marker that has been found expressed in &#x0003e;60% of GCs, with greater expression specifically in intestinal-type GCs<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. In our study, we found that <italic>CPS1</italic> to localize mostly (though not exclusively) to immature intestinal compartments. Interestingly, <italic>CPS1</italic> is an enzyme of the urea cycle and has previously been associated with GIM<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Thus far, <italic>CPS1</italic> has not been associated with stem cell biology. However, a recent report in lung cancer suggests that <italic>CPS1</italic> may be crucial for pyrimidine maintenance and DNA synthesis in <italic>KRAS</italic> mutant cells<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. Notably, <italic>KRAS</italic> was one of the driver oncogenes previously identified<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, suggesting that there may be a relevant and novel role for <italic>CPS1</italic> as a source supply of pyrimidines in the context of DNA synthesis among replicating precancerous cells.</p><p id="Par30"><italic>HKDC1</italic> is a hexokinase and has not been previously described in gastric preneoplasia. In vitro studies suggest <italic>HKDC1</italic> may promote chemoresistance, proliferation, and epithelial-to-mesenchymal transition of gastric cells through induction of NF-&#x003ba;B<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, and that <italic>HKDC1</italic> may be pivotal for glycolysis and proliferation in GC cells<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. <italic>HKDC1</italic> has been found to promote lung<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, breast<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, and biliary<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> cancers. Moreover, deletion of <italic>HKDC1</italic> inhibits proliferation and tumorigenesis in mice<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Our findings suggest <italic>HKDC1</italic> may be a novel marker for advanced gastric preneoplasia. Spatial co-expression of <italic>HKDC1</italic> and <italic>CPS1</italic> with <italic>CDX1, OLFM4</italic> and <italic>DMBT1</italic> in GIM samples, as well as GC, provide strong evidence of the potential role of these cells in metabolic reprogramming of GC precursor lesions.</p><p id="Par31">Most prior molecular and genomic studies of the GIM microenvironment have focused on populations with moderate-to-high Hp prevalence and high GC incidence<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>. Our study addresses a gap in the literature by providing needed mechanistic data on advanced GIM in a relatively low-risk population common to many regions of North America and Europe. An additional motivation for selecting Hp-negative patients for cohort development is that almost all patients diagnosed with GIM in developed nations have already undergone Hp eradication therapy&#x02014;that is to say, by the time such patients come to clinical attention they have cleared infection. There currently is no reliable test to distinguish between individuals with eradicated prior infection and no prior infection, as Hp antibody titers fall substantially in the years following clearance<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The ongoing carcinogenic potential of Hp-negative GIM may in part be explained to the establishment of clonal stem cell lineages, as suggested by this and other studies<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>.</p><p id="Par32">Our findings have public health significance. As only a small fraction of patients with GIM will progress to GC over long-term follow-up<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref></sup>, indefinite endoscopic surveillance of these patients may lead to unnecessary cost, medical risk, and anxiety. OLGIM score has been found to be significantly associated with cancer or dysplasia progression risk<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. However, the widescale adoption of OLGIM may be limited by the high interobserver variability and manually-intensive nature of its histologic calculation. The signature highlighted in this study may aid in this classification, by providing a molecular correlate to metaplastic cellularity and extent. Our study also offers molecular insight into the histologic subtyping of GIM into complete and incomplete phenotypes. One recent study using both mouse models and human participants demonstrated <italic>ANPEP</italic> expression to be strongly associated with incomplete GIM<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Another study found <italic>OLFM4</italic> to be a key marker overexpressed in human incomplete GIM samples, and that this overexpression promoted tumor-like behaviors through Wnt/&#x003b2;-catenin signaling<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Our study extends these findings by offering spatial context to the expression of both markers to immature compartments within GIM. Moreover, our results may help to explain the increased GC risk faced by individuals harboring incomplete GIM mediated through enrichment of intestinal-like stem cells.</p><p id="Par33">Our study has strengths and limitations. Our study benefited from the prospectively collected specimens (GAPS) which contained detailed histologic severity scoring (OLGIM) which is not commonly available. By contrast, public data sets of GIM were available only in broader classes of Correa&#x02019;s cascade (e.g., NAG vs CAG vs GIM). Notably however, these less-phenotyped public data sets were only used for marker refinement. Our spatial cohort was limited in size. We note that spatial validation assays are newly-emerging approaches, and that each sample in the validation steps required detailed annotation by an expert pathologist. As such, each slide represents hundreds of independent, phenotyped data points on which analysis was performed. Our study was cross-sectional in nature and did not contain longitudinal data on GIM progression. The motivation of our study was not to develop a risk-prediction model, but rather to understand molecular and cellular differences between high- and low-risk lesions. Our future studies will be focused on establishing causal inference through prospective longitudinal cohorts.</p><p id="Par34">Leveraging multiple independent cohorts, we utilized integrated transcriptomic approaches incorporating both spatial and single-cell methods to further characterize the molecular and cellular characteristics of high-risk GIM. We identified a discrete set of 26 genes which are associated with advanced OLGIM stages, localize spatially to metaplastic foci, are expressed by aberrant epithelial cells, are differentially expressed in intestinal-type GC, and can be used to distinguish mature and immature intestinal cells in GC precursors. We find that with increasing histologic severity, the expression of intestinal-like stem cell markers increase. These data hold important future implications for future cancer interception.</p></sec><sec id="Sec13"><title>Methods</title><sec id="Sec14"><title>Research ethics</title><p id="Par35">This research involved human subjects, and was performed in accordance with the Declaration of Helsinki. The human subjects research was approved by the Stanford University Institutional Review Board (approval number 45077). Informed consent to participate was obtained from all participants.</p></sec><sec id="Sec15"><title>Standard RNA-seq of gastric tissue samples</title><p id="Par36">The gastric tissue was processed using the TissueLyser LT compact bead mill (Qiagen, Venlo, Netherlands) per manufacturer&#x02019;s protocol using 5&#x02009;mm stainless steel beads in 600&#x02009;&#x000b5;L lysis buffer. AllPrep&#x000ae; DNA/RNA/miRNA Universal (Qiagen) spin column was used to bind the DNA, and RNA was extracted from the flowthrough was then used to extract the per manufacturer&#x02019;s protocol. RNA quality was assessed using Qubit RNA Broad Range Assay Kit and Qubit Fluorometer system (Thermo-Fisher Scientific, Massachusetts, USA). To assess the quality of the RNA, the samples were analyzed using the LabChip GX system (RNA Assay&#x02014;Standard Sensitivity Perkin Elmer) as per the manufacturer&#x02019;s protocol. RNA samples with an RNA quality score (RIN value) greater than 4 were then used for direct DNA library generation using the KAPA mRNA HyperPrep Library Preparation Kit (Roche). TruSeq DNA UD Indexes (Illumina) were used for adapter ligation. The KAPA Library Quantification Kit (Roche) was used for library quantification. Library quality was assessed using an iSeq 100 system and the i1 Reagent v2 (Illumina). Sequencing was conducted on an Illumina Novaseq.</p></sec><sec id="Sec16"><title>Bulk RNA-seq analysis (GAPS cohort)</title><p id="Par37">RNA sequencing reads were aligned to GRCh38 using STAR aligner version 2.7.10b. Counts per gene were generated using --quantmode GeneCounts option with STAR. We split the RNA-seq data into 2 independent sets: a discovery cohort comprising 88 paired biopsies from 46 individuals (46 antrum, 42 body; 22 high-risk OLGIM, 66 low-risk OLGIM) and a validation cohort comprising 115 individuals (215 paired patient biopsies: 115 antrum, 100 body; 22 high-risk OLGIM, 193 low-risk OLGIM).</p><p id="Par38">We used filterByExpr to filter out lowly-expressed genes followed by TMM normalization method from edgeR package in the R statistical programming environment<sup><xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Next, we performed unsupervised clustering through hierarchical clustering and principal components analysis on both the discovery and validation cohorts to confirm preferential grouping of samples into high- and low-risk OLGIM groups (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1A&#x02013;D</xref>).</p><p id="Par39">A schematic of the data analysis pipeline for the bulk RNAseq data is shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>. For both the discovery and validation data sets, we performed differential expression analysis in the same fashion. Specifically, we utilized a factorial design strategy to compare high- and low-risk lesions for each anatomic region (body and antrum). In addition, most samples had matched patient biopsies from both antrum and body: for the discovery cohort this involved 42/46 samples (91.3%) and for the validation cohort this involved 100/115 samples (87%). We used voom and duplicateCorrelation from limma<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> to estimate patient-specific weights for the regression fit, and a fold-change threshold of 1.25 was used to identify differentially expressed genes. To adjust for batch effects in the validation data set, comprised of 3 batches, we incorporated the sequencing batch as a co-variable for the regression models. Significance was set at 0.05 (FDR-adjusted P-values). In addition, we calculated the significance of the double variable (interaction term between the risk strata and anatomic region) over the differential expression profiles.</p><p id="Par40">WGCNA was conducted using WGCNA R package<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The top 15% most variable genes (<italic>N</italic>&#x02009;=&#x02009;5797) were used as input for WGCNA and normalized using the VST method in DESeq2 R package<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. A soft threshold of 16 was selected for the generation of signed weighted networks, to achieve a scale-free topology model fit R<sup>2</sup>&#x02009;&#x0003e;&#x02009;0.8 and a mean connectivity &#x0003c; 100. Informative gene modules were identified based on module-trait relationship and hierarchical clustering (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4</xref>). The differentially expressed genes were intersected with genes from informative modules from WGCNA to identify a set of genes both (i) significantly upregulated and (ii) co-expressed, common to the body and antrum of the stomach (Supplementary Fig. <xref rid="MOESM1" ref-type="media">4D</xref>). A total of 314 genes met these criteria. We conducted hierarchical clustering using the scaled expression levels of these 314 genes with ComplexHeatmap<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> in R. We identified 5 gene clusters defining high-risk GIM. We selected a subset of 105 genes from a distinct cluster with the highest Z-score (C-5) for further validation in the held-out testing set (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>).</p></sec><sec id="Sec17"><title>Validation of the high-risk expression signature</title><p id="Par41">To validate the high-risk gene expression signature, we performed differential expression analysis as described above, in the held-out testing set. Differentially expressed genes common to the body and antrum of the stomach were intersected with common differentially expressed and co-expressed genes from the body and antrum in the discovery cohort. This yielded 100/105 (95.23%) overlap between the discovery and validation sets. Functional annotation of these 100 genes was performed through over-representation analysis, with the enricher function in clusterProfiler<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup> R package. Gene sets were imported into R from Molecular Signature Database (MSigDB) using R package msigdbr.</p></sec><sec id="Sec18"><title>Spatial transcriptomics assay</title><p id="Par42">The Visium Spatial for FFPE Human Transcriptome Gene Expression Kit Gene Expression Kit (version 1) (10X Genomics) was used to prepare libraries according to the manufacturer&#x02019;s protocol. Briefly, 10&#x02009;&#x003bc;m thick tissue sections from FFPE blocks were placed on a Visium Spatial Gene Expression slide, deparaffinized and stained with hematoxylin and eosin before coverslip removal and decrosslinking. Slides were imaged using a Keyence BZ-X microscope. Probe hybridization, ligation, release, extension, and library construction were performed as per protocol using 17 cycles for sample index PCR, and libraries were sequenced on an Illumina Novaseq 6000.</p><p id="Par43">The Space Ranger (10x Genomics) version 1.3.1 mkfastq command was used to generate Fastq files, and Space Ranger version 1.3.1 count was used with default parameters and alignment to GRCh38 to perform image alignment, tissue detection, barcode and UMI counting, and generation of feature-barcode matrix. Tissue regions were annotated by a pathologist (author JS) on a hematoxylin and eosin histology images from the Visium slide.</p><p id="Par44">Raw counts were imported into the Seurat R package (version 4.3.0) and low-quality spots that detected &#x0003c;500 genes were removed. Genes detected in 3 or fewer spots were excluded, and counts were normalized with SCTransform. Spots within anatomically distinct tissue regions were labeled by unsupervised clustering refined by pathologist annotations. Spots were first clustered by FindClusters (resolution = 1.4) on the first 20 principal components and clusters marking tissue regions were annotated by pathologist annotations. Tissue regions were defined by transferring pathologist annotations to Loupe Browser (10x Genomics) version 6.1.0 to relabel any spots that did not match the pathologist annotations. Raw counts were summed from spots from each region of each patient sample to generate a pseudobulk count matrix, which was preprocessed using edgeR TMM normalization method in R. The limma-voom strategy was utilized to determine differentially expressed genes between metaplasia and spots mapping to normal gland base and pit. Gene signature scoring for each spot was performed with the AddModuleScore function in Seurat. To compare the gene signature module scores between metaplasia and normal gland pit or base regions. Normality of the data was assessed using Shapiro-Wilk test, followed by Bartlett test for homogeneity of variance and Welch T tests or Kruskal-Wallis followed by Dunn test for group comparisons.</p></sec><sec id="Sec19"><title>RNA-seq analysis from the TCGA data</title><p id="Par45">The differential expression analysis between tumor and adjacent non-tumor tissues from the TCGA RNA-seq dataset was performed to identify which of the spatially-resolved high-risk genes continued to be expressed at similar or increased patterns in cancerous tissue. We had multiple metrics and characteristics from these cancer specimens. RNA-seq data from 448 samples, including patient-matched tumor and non-tumor tissues, was downloaded and processed using GDCquery, GDCdownload and GDCprepare functions from TCGAbiolinks R package<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. The functions assay and colData from R package SummarizedExperiment were used to extract raw count matrices and sample metadata. We subset the cohort to include only intestinal-type tumors and their patient-matched control tissues (n&#x02009;=&#x02009;198; 180 tumor and 18 matched non-tumor samples) prior to filtering and normalization. Differential expression analysis was conducted using the limma-voom strategy. We used patient IDs as blocking variables for the regression models.</p></sec><sec id="Sec20"><title>Single-cell RNA sequencing</title><p id="Par46">Tissue biopsies were dissociated using a combination of enzymatic and mechanical dissociation with a gentleMACS Octo Dissociator (Miltenyi Biotec), and the resulting cells were cryofrozen using 10% DMSO in 90% FBS (ThermoFisher Scientific, Waltham, MA) in a CoolCell freezing container (Larkspur, CA) at &#x02212;80&#x02009;&#x000b0;C for 24&#x02013;72&#x02009;h followed by storage in liquid nitrogen. The cells were rapidly thawed in a bead bath at 37&#x02009;&#x000b0;C, washed twice in RPMI&#x02009;+&#x02009;10% FBS, and filtered successively through 70&#x02009;&#x003bc;m and 40&#x02009;&#x003bc;m filters (Flowmi, Bel-Art SP Scienceware, Wayne, NJ), washed, filtered, and counted using 1:1 trypan blue dilution. Cells were concentrated between 500&#x02013;1500 live cells/&#x003bc;l. The scRNA-seq libraries were generated using the Chromium Next GEM Single Cell 5&#x02019; version 2 protocol, targeting 10,000 cells with 14 PCR cycles for cDNA and library amplification. The sequencing was performed on an Illumina NovaSeq 6000.</p><p id="Par47">We used Cell Ranger (10x Genomics) version 3.1.0 mkfastq command to generate Fastq files and count with default parameters aligned to GRCh38 to generate a matrix of unique molecular identifier (UMI) counts per gene and associated cell barcodes. Seurat (version 4.0.1)<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup> was used to construct Seurat objects from each sample. Quality control filters were applied to remove low-quality cells expressing fewer than 200 genes or greater than 30% mitochondrial genes, as well as doublets with UMI counts greater than 5000 or 8000. We removed genes that were detected in less than 3 cells. Data were normalized using SCTransform and first 20 principal components with a resolution of 0.6 or 0.8 were used for clustering. We removed computationally identified doublets from each dataset using DoubletFinder (version 2.0.3)<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. The &#x02018;pN&#x02019; value was set to default value of 0.25 as the proportion of artificial doublets and the &#x02018;nExP&#x02019; was set to expected doublet rate according to Chromium Single Cell 3&#x02019; version 2 reagents kit user guide (10x Genomics). These parameters were used as input to the doubletFinder_v3 function with number of principal components set to 20 to identify doublet cells. Individual Seurat objects were merged and normalized using SCTransform. Downstream analyses requiring Seurat were conducted using version 4.4.0.</p><p id="Par48">The data sets were integrated using a soft variant of k-means clustering implemented in the Harmony algorithm (version 0.1.0)<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, using the RunHarmony function. This reduction was used in both RunUMAP and FindNeighbors functions for clustering. The first 20 principal components and a resolution of 1 were used for clustering. The data were normalized using SCTransform. The effects of variation in the mitochondrial gene percent were regressed out by in the SCTransform function. All further analyses with including differential expression analysis were conducted using data from the &#x0201c;SCT&#x0201d; assay. Major cell lineages were identified based on marker gene expression (Supplementary Fig. <xref rid="MOESM1" ref-type="media">6A</xref>). The Heatmap function from ComplexHeatmap<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, FeaturePlot, DimPlot, and VlnPlot functions from Seurat were used for visualization. Dotplots for cluster marker visualization were generated with Clustered_DotPlot function from scCustomize (version 2.1.2). We performed a secondary clustering analysis of the epithelial cells with integration across samples using Harmony and a cluster resolution of 1.0.</p><p id="Par49">Cell identity of the epithelial lineages was performed based on cell markers (Supplementary Fig. <xref rid="MOESM1" ref-type="media">7</xref>). Following label assignment, we refined our cluster labels using the output from SingleR algorithm<sup><xref ref-type="bibr" rid="CR58">58</xref></sup> as a confirmatory analysis. We used a single-cell atlas of normal stomach and duodenum as reference for automated annotation of cells<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. Briefly, counts from the reference atlas were normalized to the logarithmic scale and used as a reference for automated annotation per cell using SingleR (version 1.14.1)<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Raw counts were used to annotate test datasets. Labels were predicted for each cell in the test dataset using the &#x02018;SingleR&#x02019; function to calculate the Spearman correlation for marker genes for the reference dataset identified with Wilcoxon Rank Sum test. A second scRNAseq dataset from GC samples and patient-matched tumor-adjacent controls<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> were utilized to evaluate the 26-gene signature in GC compared to adjacent tissues activity using the AddModuleScore function in Seurat with default parameters.</p></sec><sec id="Sec21"><title>Single-molecule fluorescent in situ hybridization</title><p id="Par50">The manufacturer&#x02019;s protocol was followed to perform the RNAscope HiPlex12 Reagent Kit v2 (488, 550, 650) Assay (Advanced Cell Diagnostics Cat. No. 324419). Gastric tissue sections adjacent to those used for the Visium spatial transcriptomics assay were evaluated to identify twelve RNA target genes. The tissue sections mounted on slides were baked for 1&#x02009;h at 60&#x02009;&#x000b0;C and deparaffinized in xylene and ethanol. Target retrieval was performed using a steamer at 99&#x02009;&#x000b0;C followed by a protease treatment (Protease III for 30&#x02009;min at 40&#x02009;&#x000b0;C). Probes for the twelve genes were hybridized for 2&#x02009;h at 40&#x02009;&#x000b0;C and negative and positive control probes were run in parallel to assess sample RNA quality. A series of amplifiers were hybridized for signal amplification of single RNA transcripts for three target genes at a time which was visualized by hybridization with the first set of three cleavable fluorophores (T1-T3). Fluorophores corresponded to AF488, Dylight 550, and Dylight650. The sections were incubated with FFPE reagent for 30&#x02009;min at room temperature to reduce autofluorescence and then counterstained with DAPI for 30&#x02009;s. The sections were mounted, a cover slip was placed with ProLong Gold Antifade Mountant (Invitrogen, Cat. #P36930) and the section imaged using a Leica DMI 6000. After imaging, the coverslips were removed in a 4X SSC buffer (Sigma Aldrich, Cat. #SRE0068), and the fluorophores were cleaved using the cleaving solution from the kit. The sections were hybridized with the next set of fluorophores (T4-T6), incubated with FFPE reagent, counterstained with DAPI, and reimaged. This process was repeated four times until all 12 target genes were imaged. Next, hematoxylin and eosin staining was conducted. Whole slide images were acquired using Aperio AT2 whole slide scanner (Leica Biosystems Inc., IL, USA).</p><p id="Par51">Imaging was performed on a Leica DMI 6000 microscope with a 40X (NA 0.85) air objective. The microscope was controlled using the Lecia Application Suite X (LAS X) v3.6.0 software. The exposure and gain were qualitatively calibrated for each channel (DAPI, Alexa Fluor-488, Dylight 550, Dylight 650) and re-adjusted each round. To capture whole-slide images of the samples, we used the Tilescan function in LAS X to automatically acquire many image tiles using the motorized stage. The image tiles were acquired with 20% overlap to enable downstream stitching into whole-slide images. These images were exported from LAS X in .lif file format.</p><p id="Par52">We inputted the .lif files from each sample into MCMICRO<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, a microscopy image processing pipeline for multiplexed images. Within the MCMICRO pipeline, we first corrected for uneven illumination by applying the BaSiC algorithm<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. Next, we use ASHLAR<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> to simultaneously stitch individual image tiles into whole-slide-images and register channels across multiple imaging rounds using the DAPI channel as a reference. Finally, for each sample we exported a multiplexed whole-slide OME-TIFF image containing all channels across all imaging rounds. We viewed these images with QuPath<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> v0.5.1 and manually adjusted the channel minimum and maximum for each imaging channel across every round to minimize background noise and enhance contrast. We exported snapshots in svg format to display in figures.</p></sec></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41698_2025_816_MOESM1_ESM.pdf"><caption><p>Supplemental</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41698_2025_816_MOESM2_ESM.xlsx"><caption><p>Supplementary Data (1 - 15).</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>These authors contributed equally: Robert J. Huang, Ignacio A. Wichmann.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41698-025-00816-w.</p></sec><ack><title>Acknowledgements</title><p>Funding for this work came from NIH grants P01CA26577 to I.A.W., R.J.H., A.S., M.V.S., S.M.G., R.M., A.A., X.B., J.S., S.S.H., M.R.A., J.H.H., H.P.J., R01HG006137 to H.P.J., I.A.W. H.P.J. was additionally supported from the Gastric Cancer Foundation and the Clayville Foundation. RJH was additionally supported by the NCI/NIH under Award Number K08CA252635. IAW was additionally supported by CONICYT FONDAP 15130011 and ANID FONDAP apoyo 1523A0008. MVS was supported by the Xie Foundation. Advanced Cell Diagnostics provided RNAScope HiPlex reagents, received as part of the spatial grant program to IAW.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>R.J.H. co-led manuscript writing, co-led conception and design, and co-led specimen collection. I.A.W. co-led manuscript writing, led bioinformatics and statistical analysis, drafted figures, and co-led interpretation of data. A.S. contributed to statistical analysis, interpretation of data, and figure creation. A.S. performed experimentation including scRNA-seq and data analysis. M.V.S. performed specimen collection, specimen processing, and table generation. S.G. performed bioinformatics analysis. R.M. performed experiments in support of smFISH. A.A. performed data collection, specimen collection, and specimen processing. X.B. performed statistical analysis. J.S. interpreted and annotated biopsies. Q.N. assisted in the bioinformatics analysis. MRA contributed to conception, design, and image generation. J.H.H. co-led conception and design, co-led specimen collection. H.P.J. co-led conception and design and provided overall administrative oversight over the project. All authors participated in drafting the manuscript for important intellectual content and gave approval for publication.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data from this study has been deposited in phs003648.v1.p1. Downloaded datasets are available under accession numbers phs001818, GSE134520, GSE150290, and PRJNA678538.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The code used in this study can be accessed at <ext-link ext-link-type="uri" xlink:href="https://github.com/sgtc-stanford/GIM-spatial">https://github.com/sgtc-stanford/GIM-spatial</ext-link>.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par53">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <italic>CA Cancer J. Clin.</italic><bold>71</bold>, 209&#x02013;249 (2021).<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Allemani</surname><given-names>C</given-names></name><etal/></person-group><article-title>Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries</article-title><source>Lancet</source><year>2018</year><volume>391</volume><fpage>1023</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33326-3</pub-id><pub-id pub-id-type="pmid">29395269</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Allemani, C. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <italic>Lancet</italic><bold>391</bold>, 1023&#x02013;1075 (2018).<pub-id pub-id-type="pmid">29395269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>P</given-names></name></person-group><article-title>Human gastric carcinogenesis: a multistep and multifactorial process&#x02013;First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><fpage>6735</fpage><lpage>6740</lpage><pub-id pub-id-type="pmid">1458460</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Correa, P. Human gastric carcinogenesis: a multistep and multifactorial process&#x02013;First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. <italic>Cancer Res</italic>. <bold>52</bold>, 6735&#x02013;6740 (1992).<pub-id pub-id-type="pmid">1458460</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnenberg</surname><given-names>A</given-names></name><name><surname>Lash</surname><given-names>RH</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name></person-group><article-title>A national study of Helicobactor pylori infection in gastric biopsy specimens</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1894</fpage><lpage>1901.e1892</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.08.018</pub-id><pub-id pub-id-type="pmid">20727889</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sonnenberg, A., Lash, R. H. &#x00026; Genta, R. M. A national study of Helicobactor pylori infection in gastric biopsy specimens. <italic>Gastroenterology</italic><bold>139</bold>, 1894&#x02013;1901.e1892 (2010).<pub-id pub-id-type="pmid">20727889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnenberg</surname><given-names>A</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name></person-group><article-title>Changes in the gastric mucosa with aging</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2015</year><volume>13</volume><fpage>2276</fpage><lpage>2281</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2015.02.020</pub-id><pub-id pub-id-type="pmid">25724703</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sonnenberg, A. &#x00026; Genta, R. M. Changes in the gastric mucosa with aging. <italic>Clin. Gastroenterol. Hepatol.</italic><bold>13</bold>, 2276&#x02013;2281 (2015).<pub-id pub-id-type="pmid">25724703</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands</article-title><source>Gastroenterology</source><year>2008</year><volume>134</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.01.071</pub-id><pub-id pub-id-type="pmid">18395075</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">de Vries, A. C. et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. <italic>Gastroenterology</italic><bold>134</bold>, 945&#x02013;952 (2008).<pub-id pub-id-type="pmid">18395075</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><etal/></person-group><article-title>Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population</article-title><source>BMJ</source><year>2015</year><volume>351</volume><fpage>h3867</fpage><pub-id pub-id-type="doi">10.1136/bmj.h3867</pub-id><pub-id pub-id-type="pmid">26215280</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Song, H. et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. <italic>BMJ</italic><bold>351</bold>, h3867 (2015).<pub-id pub-id-type="pmid">26215280</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Capelle</surname><given-names>LG</given-names></name><etal/></person-group><article-title>The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis</article-title><source>Gastrointest. Endosc.</source><year>2010</year><volume>71</volume><fpage>1150</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2009.12.029</pub-id><pub-id pub-id-type="pmid">20381801</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Capelle, L. G. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. <italic>Gastrointest. Endosc.</italic><bold>71</bold>, 1150&#x02013;1158 (2010).<pub-id pub-id-type="pmid">20381801</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>MF</given-names></name><name><surname>Genta</surname><given-names>RM</given-names></name><name><surname>Yardley</surname><given-names>JH</given-names></name><name><surname>Correa</surname><given-names>P</given-names></name></person-group><article-title>Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994</article-title><source>Am. J. Surg. Pathol.</source><year>1996</year><volume>20</volume><fpage>1161</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1097/00000478-199610000-00001</pub-id><pub-id pub-id-type="pmid">8827022</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Dixon, M. F., Genta, R. M., Yardley, J. H. &#x00026; Correa, P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. <italic>Am. J. Surg. Pathol.</italic><bold>20</bold>, 1161&#x02013;1181 (1996).<pub-id pub-id-type="pmid">8827022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Rugge</surname><given-names>M</given-names></name><etal/></person-group><article-title>OLGA staging for gastritis: a tutorial</article-title><source>Dig. Liver Dis.</source><year>2008</year><volume>40</volume><fpage>650</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2008.02.030</pub-id><pub-id pub-id-type="pmid">18424244</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Rugge, M. et al. OLGA staging for gastritis: a tutorial. <italic>Dig. Liver Dis.</italic><bold>40</bold>, 650&#x02013;658 (2008).<pub-id pub-id-type="pmid">18424244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JWJ</given-names></name><etal/></person-group><article-title>Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)</article-title><source>Gut</source><year>2022</year><volume>71</volume><fpage>854</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2021-324057</pub-id><pub-id pub-id-type="pmid">33975867</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Lee, J. W. J. et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). <italic>Gut</italic><bold>71</bold>, 854&#x02013;863 (2022).<pub-id pub-id-type="pmid">33975867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Latorre, G. et al. Comparison of OLGA and OLGIM as predictors of gastric cancer in a Latin American population: The ECHOS Study. <italic>Gut</italic>10.1136/gutjnl-2023-331059 (2023).</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>M</given-names></name><etal/></person-group><article-title>British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>1545</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-318126</pub-id><pub-id pub-id-type="pmid">31278206</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Banks, M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. <italic>Gut</italic><bold>68</bold>, 1545&#x02013;1575 (2019).<pub-id pub-id-type="pmid">31278206</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel-Nunes</surname><given-names>P</given-names></name><etal/></person-group><article-title>Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019</article-title><source>Endoscopy</source><year>2019</year><volume>51</volume><fpage>365</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1055/a-0859-1883</pub-id><pub-id pub-id-type="pmid">30841008</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Pimentel-Nunes, P. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. <italic>Endoscopy</italic><bold>51</bold>, 365&#x02013;388 (2019).<pub-id pub-id-type="pmid">30841008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Cancer Genome Atlas Research, N. Comprehensive molecular characterization of gastric adenocarcinoma. <italic>Nature</italic><bold>513</bold>, 202-209 10.1038/nature13480 (2014).</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Colaprico</surname><given-names>A</given-names></name><etal/></person-group><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title><source>Nucleic Acids Res</source><year>2016</year><volume>44</volume><fpage>e71</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv1507</pub-id><pub-id pub-id-type="pmid">26704973</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Colaprico, A. et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. <italic>Nucleic Acids Res</italic>. <bold>44</bold>, e71 (2016).<pub-id pub-id-type="pmid">26704973</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><etal/></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>e47</fpage><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. <italic>Nucleic Acids Res</italic>. <bold>43</bold>, e47 (2015).<pub-id pub-id-type="pmid">25605792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Langfelder</surname><given-names>P</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name></person-group><article-title>WGCNA: an R package for weighted correlation network analysis</article-title><source>BMC Bioinforma.</source><year>2008</year><volume>9</volume><fpage>559</fpage><pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Langfelder, P. &#x00026; Horvath, S. WGCNA: an R package for weighted correlation network analysis. <italic>BMC Bioinforma.</italic><bold>9</bold>, 559 (2008).</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahara</surname><given-names>K</given-names></name></person-group><article-title>Special features of intestinal metaplasia and its relation to early gastric carcinoma in man: observation by a method in which leucine aminopeptidase activity is used</article-title><source>J. Natl Cancer Inst.</source><year>1978</year><volume>61</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">278846</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Nakahara, K. Special features of intestinal metaplasia and its relation to early gastric carcinoma in man: observation by a method in which leucine aminopeptidase activity is used. <italic>J. Natl Cancer Inst.</italic><bold>61</bold>, 693&#x02013;701 (1978).<pub-id pub-id-type="pmid">278846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>213</fpage><lpage>225.e213</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.04.008</pub-id><pub-id pub-id-type="pmid">20398667</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lee, H. J. et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. <italic>Gastroenterology</italic><bold>139</bold>, 213&#x02013;225.e213 (2010).<pub-id pub-id-type="pmid">20398667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>van der Flier</surname><given-names>LG</given-names></name><name><surname>Haegebarth</surname><given-names>A</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells</article-title><source>Gastroenterology</source><year>2009</year><volume>137</volume><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.05.035</pub-id><pub-id pub-id-type="pmid">19450592</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">van der Flier, L. G., Haegebarth, A., Stange, D. E., van de Wetering, M. &#x00026; Clevers, H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. <italic>Gastroenterology</italic><bold>137</bold>, 15&#x02013;17 (2009).<pub-id pub-id-type="pmid">19450592</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Gulaia</surname><given-names>V</given-names></name><etal/></person-group><article-title>Molecular mechanisms governing the stem cell&#x02019;s fate in brain cancer: Factors of stemness and quiescence</article-title><source>Front Cell Neurosci.</source><year>2018</year><volume>12</volume><fpage>388</fpage><pub-id pub-id-type="doi">10.3389/fncel.2018.00388</pub-id><pub-id pub-id-type="pmid">30510501</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Gulaia, V. et al. Molecular mechanisms governing the stem cell&#x02019;s fate in brain cancer: Factors of stemness and quiescence. <italic>Front Cell Neurosci.</italic><bold>12</bold>, 388 (2018).<pub-id pub-id-type="pmid">30510501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><etal/></person-group><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innov. (Camb.)</source><year>2021</year><volume>2</volume><fpage>100141</fpage></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. <italic>Innov. (Camb.)</italic><bold>2</bold>, 100141 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><year>2012</year><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Yu, G., Wang, L. G., Han, Y. &#x00026; He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. <italic>OMICS</italic><bold>16</bold>, 284&#x02013;287 (2012).<pub-id pub-id-type="pmid">22455463</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Busslinger</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Human gastrointestinal epithelia of the esophagus, stomach, and duodenum resolved at single-cell resolution</article-title><source>Cell Rep.</source><year>2021</year><volume>34</volume><fpage>108819</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108819</pub-id><pub-id pub-id-type="pmid">33691112</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Busslinger, G. A. et al. Human gastrointestinal epithelia of the esophagus, stomach, and duodenum resolved at single-cell resolution. <italic>Cell Rep.</italic><bold>34</bold>, 108819 (2021).<pub-id pub-id-type="pmid">33691112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencing</article-title><source>Nat. Cell Biol.</source><year>2018</year><volume>20</volume><fpage>721</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0105-4</pub-id><pub-id pub-id-type="pmid">29802404</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gao, S. et al. Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencing. <italic>Nat. Cell Biol.</italic><bold>20</bold>, 721&#x02013;734 (2018).<pub-id pub-id-type="pmid">29802404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Molecular Signatures Database (MSigDB) hallmark gene set collection</article-title><source>Cell Syst.</source><year>2015</year><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. <italic>Cell Syst.</italic><bold>1</bold>, 417&#x02013;425 (2015).<pub-id pub-id-type="pmid">26771021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><article-title>Integrating single-cell transcriptomic data across different conditions, technologies, and species</article-title><source>Nat. Biotechnol.</source><year>2018</year><volume>36</volume><fpage>411</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1038/nbt.4096</pub-id><pub-id pub-id-type="pmid">29608179</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Butler, A., Hoffman, P., Smibert, P., Papalexi, E. &#x00026; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. <italic>Nat. Biotechnol.</italic><bold>36</bold>, 411&#x02013;420 (2018).<pub-id pub-id-type="pmid">29608179</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Hafemeister</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><article-title>Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression</article-title><source>Genome Biol.</source><year>2019</year><volume>20</volume><fpage>296</fpage><pub-id pub-id-type="doi">10.1186/s13059-019-1874-1</pub-id><pub-id pub-id-type="pmid">31870423</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hafemeister, C. &#x00026; Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. <italic>Genome Biol.</italic><bold>20</bold>, 296 (2019).<pub-id pub-id-type="pmid">31870423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>WM</given-names></name><name><surname>Poulsom</surname><given-names>R</given-names></name><name><surname>Wright</surname><given-names>NA</given-names></name></person-group><article-title>Trefoil peptides</article-title><source>Gut</source><year>1999</year><volume>44</volume><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1136/gut.44.6.890</pub-id><pub-id pub-id-type="pmid">10323896</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Wong, W. M., Poulsom, R. &#x00026; Wright, N. A. Trefoil peptides. <italic>Gut</italic><bold>44</bold>, 890&#x02013;895 (1999).<pub-id pub-id-type="pmid">10323896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Kjellev</surname><given-names>S</given-names></name></person-group><article-title>The trefoil factor family - small peptides with multiple functionalities</article-title><source>Cell Mol. Life Sci.</source><year>2009</year><volume>66</volume><fpage>1350</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1007/s00018-008-8646-5</pub-id><pub-id pub-id-type="pmid">19099184</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kjellev, S. The trefoil factor family - small peptides with multiple functionalities. <italic>Cell Mol. Life Sci.</italic><bold>66</bold>, 1350&#x02013;1369 (2009).<pub-id pub-id-type="pmid">19099184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sathe</surname><given-names>A</given-names></name><etal/></person-group><article-title>Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment</article-title><source>Clin. Cancer Res</source><year>2020</year><volume>26</volume><fpage>2640</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3231</pub-id><pub-id pub-id-type="pmid">32060101</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sathe, A. et al. Single-cell genomic characterization reveals the cellular reprogramming of the gastric tumor microenvironment. <italic>Clin. Cancer Res</italic><bold>26</bold>, 2640&#x02013;2653 (2020).<pub-id pub-id-type="pmid">32060101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>2019</fpage><lpage>2037.e2018</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.10.004</pub-id><pub-id pub-id-type="pmid">37890493</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Huang, K. K. et al. Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression. <italic>Cancer Cell</italic><bold>41</bold>, 2019&#x02013;2037.e2018 (2023).<pub-id pub-id-type="pmid">37890493</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Nowicki-Osuch</surname><given-names>K</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>1346</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-0824</pub-id><pub-id pub-id-type="pmid">36929873</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Nowicki-Osuch, K. et al. Single-cell RNA sequencing unifies developmental programs of esophageal and gastric intestinal metaplasia. <italic>Cancer Discov.</italic><bold>13</bold>, 1346&#x02013;1363 (2023).<pub-id pub-id-type="pmid">36929873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Zou</surname><given-names>WY</given-names></name></person-group><article-title>Guilt by association: intestinal metaplasia does not progress to gastric cancer</article-title><source>Curr. Opin. Gastroenterol.</source><year>2018</year><volume>34</volume><fpage>458</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1097/MOG.0000000000000472</pub-id><pub-id pub-id-type="pmid">30138135</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Graham, D. Y. &#x00026; Zou, W. Y. Guilt by association: intestinal metaplasia does not progress to gastric cancer. <italic>Curr. Opin. Gastroenterol.</italic><bold>34</bold>, 458&#x02013;464 (2018).<pub-id pub-id-type="pmid">30138135</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>PG</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Weiss</surname><given-names>LM</given-names></name></person-group><article-title>Hepatocyte antigen as a marker of intestinal metaplasia</article-title><source>Am. J. Surg. Pathol.</source><year>2003</year><volume>27</volume><fpage>952</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1097/00000478-200307000-00010</pub-id><pub-id pub-id-type="pmid">12826887</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Chu, P. G., Jiang, Z. &#x00026; Weiss, L. M. Hepatocyte antigen as a marker of intestinal metaplasia. <italic>Am. J. Surg. Pathol.</italic><bold>27</bold>, 952&#x02013;959 (2003).<pub-id pub-id-type="pmid">12826887</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><etal/></person-group><article-title>CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells</article-title><source>Nature</source><year>2017</year><volume>546</volume><fpage>168</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/nature22359</pub-id><pub-id pub-id-type="pmid">28538732</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Kim, J. et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. <italic>Nature</italic><bold>546</bold>, 168&#x02013;172 (2017).<pub-id pub-id-type="pmid">28538732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>MQ</given-names></name><etal/></person-group><article-title>HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer</article-title><source>Cancer Sci.</source><year>2023</year><volume>114</volume><fpage>1365</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1111/cas.15692</pub-id><pub-id pub-id-type="pmid">36519789</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wang, M. Q. et al. HKDC1 upregulation promotes glycolysis and disease progression, and confers chemoresistance onto gastric cancer. <italic>Cancer Sci.</italic><bold>114</bold>, 1365&#x02013;1377 (2023).<pub-id pub-id-type="pmid">36519789</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Bao</surname><given-names>TT</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>JW</given-names></name><name><surname>Feng</surname><given-names>JF</given-names></name></person-group><article-title>HKDC1 silencing inhibits proliferation and glycolysis of gastric cancer cells</article-title><source>J. Oncol.</source><year>2023</year><volume>2023</volume><fpage>3876342</fpage><pub-id pub-id-type="doi">10.1155/2023/3876342</pub-id><pub-id pub-id-type="pmid">37153834</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Yu, C., Bao, T. T., Jin, L., Lu, J. W. &#x00026; Feng, J. F. HKDC1 silencing inhibits proliferation and glycolysis of gastric cancer cells. <italic>J. Oncol.</italic><bold>2023</bold>, 3876342 (2023).<pub-id pub-id-type="pmid">37153834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>450</fpage><pub-id pub-id-type="doi">10.1186/s12935-020-01539-7</pub-id><pub-id pub-id-type="pmid">32943998</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Wang, X. et al. HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway. <italic>Cancer Cell Int</italic>. <bold>20</bold>, 450 (2020).<pub-id pub-id-type="pmid">32943998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>PGC1beta regulates breast tumor growth and metastasis by SREBP1-mediated HKDC1 expression</article-title><source>Front Oncol.</source><year>2019</year><volume>9</volume><fpage>290</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00290</pub-id><pub-id pub-id-type="pmid">31058090</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Chen, X. et al. PGC1beta regulates breast tumor growth and metastasis by SREBP1-mediated HKDC1 expression. <italic>Front Oncol.</italic><bold>9</bold>, 290 (2019).<pub-id pub-id-type="pmid">31058090</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><etal/></person-group><article-title>Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>70</fpage><lpage>87.e15</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.12.006</pub-id><pub-id pub-id-type="pmid">34971568</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. <italic>Cancer Cell</italic><bold>40</bold>, 70&#x02013;87.e15 (2022).<pub-id pub-id-type="pmid">34971568</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MW</given-names></name><etal/></person-group><article-title>The hexokinase &#x0201c;HKDC1&#x0201d; interaction with the mitochondria is essential for liver cancer progression</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>660</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-04999-z</pub-id><pub-id pub-id-type="pmid">35902556</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Khan, M. W. et al. The hexokinase &#x0201c;HKDC1&#x0201d; interaction with the mitochondria is essential for liver cancer progression. <italic>Cell Death Dis.</italic><bold>13</bold>, 660 (2022).<pub-id pub-id-type="pmid">35902556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer</article-title><source>Cancer Cell</source><year>2018</year><volume>33</volume><fpage>137</fpage><lpage>150.e135</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.11.018</pub-id><pub-id pub-id-type="pmid">29290541</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Huang, K. K. et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. <italic>Cancer Cell</italic><bold>33</bold>, 137&#x02013;150.e135 (2018).<pub-id pub-id-type="pmid">29290541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumagai</surname><given-names>K</given-names></name><etal/></person-group><article-title>Expansion of gastric intestinal metaplasia with copy number aberrations contributes to field cancerization</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><fpage>1712</fpage><lpage>1723</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-1523</pub-id><pub-id pub-id-type="pmid">35363856</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kumagai, K. et al. Expansion of gastric intestinal metaplasia with copy number aberrations contributes to field cancerization. <italic>Cancer Res</italic><bold>82</bold>, 1712&#x02013;1723 (2022).<pub-id pub-id-type="pmid">35363856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long-term response of helicobacter pylori antibody titer after eradication treatment in middle-aged Japanese: JPHC-NEXT study</article-title><source>J. Epidemiol.</source><year>2023</year><volume>33</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2188/jea.JE20200618</pub-id><pub-id pub-id-type="pmid">33907066</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Tanaka, S. et al. Long-term response of helicobacter pylori antibody titer after eradication treatment in middle-aged Japanese: JPHC-NEXT study. <italic>J. Epidemiol.</italic><bold>33</bold>, 1&#x02013;7 (2023).<pub-id pub-id-type="pmid">33907066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: A population-based study</article-title><source>Am. J. Gastroenterol.</source><year>2016</year><volume>111</volume><fpage>1104</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1038/ajg.2016.188</pub-id><pub-id pub-id-type="pmid">27185078</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Li, D. et al. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: A population-based study. <italic>Am. J. Gastroenterol.</italic><bold>111</bold>, 1104&#x02013;1113 (2016).<pub-id pub-id-type="pmid">27185078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>KM</given-names></name><name><surname>Chang</surname><given-names>JI</given-names></name><name><surname>Shi</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>BU</given-names></name></person-group><article-title>Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2016</year><volume>14</volume><fpage>1420</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2016.05.045</pub-id><pub-id pub-id-type="pmid">27317852</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Reddy, K. M., Chang, J. I., Shi, J. M. &#x00026; Wu, B. U. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. <italic>Clin. Gastroenterol. Hepatol.</italic><bold>14</bold>, 1420&#x02013;1425 (2016).<pub-id pub-id-type="pmid">27317852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Spence</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review</article-title><source>BMC Gastroenterol.</source><year>2017</year><volume>17</volume><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s12876-017-0708-4</pub-id><pub-id pub-id-type="pmid">29228909</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Spence, A. D. et al. Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review. <italic>BMC Gastroenterol.</italic><bold>17</bold>, 157 (2017).<pub-id pub-id-type="pmid">29228909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Hoft, S. G. et al. Unveiling cancer-related metaplastic cells in both helicobacter pylori infection and autoimmune gastritis. <italic>Gastroenterology</italic>10.1053/j.gastro.2024.08.032 (2024).</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>H</given-names></name><etal/></person-group><article-title>OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3beta/beta-catenin pathway</article-title><source>Mol. Cancer</source><year>2024</year><volume>23</volume><fpage>124</fpage><pub-id pub-id-type="doi">10.1186/s12943-024-02016-9</pub-id><pub-id pub-id-type="pmid">38849840</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Wei, H. et al. OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3beta/beta-catenin pathway. <italic>Mol. Cancer</italic><bold>23</bold>, 124 (2024).<pub-id pub-id-type="pmid">38849840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>G</given-names></name></person-group><article-title>K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Robinson, M. D., McCarthy, D. J. &#x00026; Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. <italic>Bioinformatics</italic><bold>26</bold>, 139&#x02013;140 (2010).<pub-id pub-id-type="pmid">19910308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>4288</fpage><lpage>4297</lpage><pub-id pub-id-type="doi">10.1093/nar/gks042</pub-id><pub-id pub-id-type="pmid">22287627</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">McCarthy, D. J., Chen, Y. &#x00026; Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. <italic>Nucleic Acids Res</italic>. <bold>40</bold>, 4288&#x02013;4297 (2012).<pub-id pub-id-type="pmid">22287627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol.</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Love, M. I., Huber, W. &#x00026; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. <italic>Genome Biol.</italic><bold>15</bold>, 550 (2014).<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name></person-group><article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title><source>Bioinformatics</source><year>2016</year><volume>32</volume><fpage>2847</fpage><lpage>2849</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw313</pub-id><pub-id pub-id-type="pmid">27207943</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Gu, Z., Eils, R. &#x00026; Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. <italic>Bioinformatics</italic><bold>32</bold>, 2847&#x02013;2849 (2016).<pub-id pub-id-type="pmid">27207943</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>McGinnis</surname><given-names>CS</given-names></name><name><surname>Murrow</surname><given-names>LM</given-names></name><name><surname>Gartner</surname><given-names>ZJ</given-names></name></person-group><article-title>DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors</article-title><source>Cell Syst.</source><year>2019</year><volume>8</volume><fpage>329</fpage><lpage>337.e324</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2019.03.003</pub-id><pub-id pub-id-type="pmid">30954475</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">McGinnis, C. S., Murrow, L. M. &#x00026; Gartner, Z. J. DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. <italic>Cell Syst.</italic><bold>8</bold>, 329&#x02013;337.e324 (2019).<pub-id pub-id-type="pmid">30954475</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Korsunsky</surname><given-names>I</given-names></name><etal/></person-group><article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title><source>Nat. Methods</source><year>2019</year><volume>16</volume><fpage>1289</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id><pub-id pub-id-type="pmid">31740819</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. <italic>Nat. Methods</italic><bold>16</bold>, 1289&#x02013;1296 (2019).<pub-id pub-id-type="pmid">31740819</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title><source>Nat. Immunol.</source><year>2019</year><volume>20</volume><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0276-y</pub-id><pub-id pub-id-type="pmid">30643263</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. <italic>Nat. Immunol.</italic><bold>20</bold>, 163&#x02013;172 (2019).<pub-id pub-id-type="pmid">30643263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Schapiro</surname><given-names>D</given-names></name><etal/></person-group><article-title>MCMICRO: A scalable, modular image-processing pipeline for multiplexed tissue imaging</article-title><source>Nat. Methods</source><year>2022</year><volume>19</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/s41592-021-01308-y</pub-id><pub-id pub-id-type="pmid">34824477</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Schapiro, D. et al. MCMICRO: A scalable, modular image-processing pipeline for multiplexed tissue imaging. <italic>Nat. Methods</italic><bold>19</bold>, 311&#x02013;315 (2022).<pub-id pub-id-type="pmid">34824477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>T</given-names></name><etal/></person-group><article-title>A BaSiC tool for background and shading correction of optical microscopy images</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14836</fpage><pub-id pub-id-type="doi">10.1038/ncomms14836</pub-id><pub-id pub-id-type="pmid">28594001</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Peng, T. et al. A BaSiC tool for background and shading correction of optical microscopy images. <italic>Nat. Commun.</italic><bold>8</bold>, 14836 (2017).<pub-id pub-id-type="pmid">28594001</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Muhlich</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><fpage>4613</fpage><lpage>4621</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btac544</pub-id><pub-id pub-id-type="pmid">35972352</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Muhlich, J. L. et al. Stitching and registering highly multiplexed whole-slide images of tissues and tumors using ASHLAR. <italic>Bioinformatics</italic><bold>38</bold>, 4613&#x02013;4621 (2022).<pub-id pub-id-type="pmid">35972352</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><etal/></person-group><article-title>QuPath: Open source software for digital pathology image analysis</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>16878</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17204-5</pub-id><pub-id pub-id-type="pmid">29203879</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. <italic>Sci. Rep.</italic><bold>7</bold>, 16878 (2017).<pub-id pub-id-type="pmid">29203879</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>